Regulatory T-cell (Treg) Therapy

Retraining the immune system to stand down instead of attack.

Most immunotherapy tries to rev up the immune system. Treg therapy does the opposite. Regulatory T-cells are the immune system's brakes; in autoimmune disease those brakes fail and the body attacks itself. The idea is to isolate, expand and reinfuse a patient's Tregs to restore tolerance.

Lead targets are type-1 diabetes (protecting insulin-producing cells before they're destroyed) and multiple sclerosis. Next-gen approaches make Tregs antigen-specific so they suppress only the harmful response. Poland's PolTREG is one of the world's furthest-along developers.

How it works in depth

Most immunotherapies dial the immune system up. Treg therapy does the opposite: it deploys regulatory T cells, a specialized subset defined by the master transcription factor FOXP3, to actively suppress unwanted immune attacks and restore tolerance. The biology behind this won the 2025 Nobel Prize in Physiology or Medicine, awarded to Shimon Sakaguchi, Mary Brunkow, and Fred Ramsdell for discoveries concerning peripheral immune tolerance. Sakaguchi identified the cells in 1995 (marked by CD25); Brunkow and Ramsdell linked FOXP3 mutations to the lethal autoimmune disorder IPEX in 2001.

Therapeutically, Tregs are either expanded from a patient's own blood (polyclonal) or engineered to act where disease lives. CAR-Tregs carry a chimeric antigen receptor (for example, targeting HLA on a transplanted organ); TCR-Tregs express a T-cell receptor recognizing a specific self-antigen, such as a myelin fragment in multiple sclerosis. Once homed to the target tissue, Tregs suppress inflammation locally, can recruit and convert other immune cells ("linked suppression" and "infectious tolerance"), and in principle offer durable, antigen-specific control without broad immunosuppression.

Where the field is in 2025-2026

The field is still early-stage but accelerating, with dozens of clinical trials reported across autoimmune, inflammatory, and transplant indications. Manufacturing remains a central challenge: Tregs are rare, hard to expand while keeping a stable phenotype, and the autologous cell-therapy model is costly. A key debate is whether engineered, antigen-specific Tregs (CAR/TCR) will outperform polyclonal Tregs and low-dose IL-2 approaches that simply boost endogenous Tregs. As of 2025, the human efficacy data is largely interim and early, so durability and dosing are still open questions.

Leading programs & players

Sonoma Biotherapeutics (co-founded by Nobel laureate Fred Ramsdell, with a Regeneron collaboration) reported positive interim Phase 1 safety and efficacy data for its engineered Treg therapy SBT-77-7101 in refractory rheumatoid arthritis from the REGULATE-RA study in October 2025. Quell Therapeutics has an AstraZeneca deal (reportedly ~$85M upfront) for CAR-Treg programs in type 1 diabetes and IBD; it reportedly paused its QEL-001 liver-transplant program to prioritize a newer candidate. Sangamo Therapeutics is advancing TX200, an HLA-A2 CAR-Treg, in kidney transplantation. Abata Therapeutics received FDA Fast Track for ABA-101, a TCR-engineered Treg for progressive multiple sclerosis (Phase 1, NCT06566261). Adjacent Treg-enhancing approaches include Coya Therapeutics' COYA 301 (low-dose IL-2) in ALS. The market outlook is high-risk but high-reward: success in even one chronic autoimmune indication could validate tolerance induction as a durable alternative to lifelong immunosuppression.

FAQ

What is regulatory T-cell (Treg) therapy?

It is a cell therapy that uses or engineers FOXP3+ regulatory T cells to suppress harmful immune responses and restore tolerance, aiming to treat autoimmune disease, inflammation, and transplant rejection rather than boost immunity.

How is Treg therapy different from CAR-T cancer therapy?

CAR-T for cancer activates killer T cells to destroy tumor cells. Treg therapy does the reverse, deploying suppressive regulatory T cells to calm the immune system. CAR-Tregs use similar receptor engineering but to localize tolerance instead of cytotoxicity.

Are any Treg therapies approved as of 2025-2026?

No Treg cell therapy is FDA-approved yet. Programs are in early clinical development. Sonoma Biotherapeutics reported positive interim Phase 1 data in rheumatoid arthritis in October 2025, and others from Sangamo, Abata, and Quell are in or near the clinic.

Which companies are leading Treg therapy development?

Notable players include Sonoma Biotherapeutics (SBT-77-7101, rheumatoid arthritis), Sangamo Therapeutics (TX200, kidney transplant), Abata Therapeutics (ABA-101, progressive MS), Quell Therapeutics (CAR-Tregs with AstraZeneca), and Coya Therapeutics (Treg-enhancing IL-2 approaches).

Companies working on Regulatory T-cell (Treg) Therapy

Explore the interactive landscapes →